(Zacks Equity Research)
GlaxoSmithKline’s (GSK - Analyst Report) diabetes candidate, Eperzan (albiglutide) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). A final decision from the European Commission should be out by the end of this quarter.
The CHMP recommended the approval of Eperzan both as a monotherapy and as combination therapy in adults suffering from type II diabetes. The CHMP’s positive recommendation was based on encouraging data from eight phase III trials on Eperzan.
Eperzan is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being developed as a once-weekly treatment for type II diabetes. We are encouraged with the CHMP recommendation on Eperzan, which can provide an edge over daily dosing regime of GLP-1 products including Novo Nordisk’s (NVO - Analyst Report) Victoza among others. Currently, Bydureon is the only GLP-1 receptor agonist which has once weekly dosing.
Read the full article on Zacks.com